MML Investors Services LLC Invests $452,000 in RxSight, Inc. (NASDAQ:RXST)

MML Investors Services LLC purchased a new stake in RxSight, Inc. (NASDAQ:RXST) during the third quarter, according to its most recent filing with the SEC. The firm purchased 9,154 shares of the company’s stock, valued at approximately $452,000.

Several other hedge funds and other institutional investors have also bought and sold shares of RXST. Nisa Investment Advisors LLC raised its holdings in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quarry LP increased its position in shares of RxSight by 82.3% in the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in RxSight during the 3rd quarter worth $34,000. Quest Partners LLC bought a new position in RxSight during the second quarter worth about $41,000. Finally, KBC Group NV grew its stake in RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after acquiring an additional 479 shares during the period. Institutional investors own 78.78% of the company’s stock.

Insider Activity

In other news, insider Ilya Goldshleger sold 1,330 shares of RxSight stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $46.13, for a total value of $61,352.90. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $1,948,807.98. This trade represents a 3.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jesse Anderson Corley acquired 11,111 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the purchase, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 59,607 shares of company stock worth $2,874,109 in the last quarter. Corporate insiders own 9.36% of the company’s stock.

RxSight Trading Up 2.8 %

Shares of RXST stock opened at $34.59 on Tuesday. The firm’s fifty day moving average price is $45.75 and its two-hundred day moving average price is $49.98. RxSight, Inc. has a 1 year low of $33.03 and a 1 year high of $66.54. The firm has a market capitalization of $1.39 billion, a P/E ratio of -41.67 and a beta of 1.11.

Analysts Set New Price Targets

RXST has been the topic of a number of research analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $42.00 price target (down previously from $56.00) on shares of RxSight in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. UBS Group began coverage on shares of RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective on the stock. Finally, Stifel Nicolaus lowered shares of RxSight from a “buy” rating to a “hold” rating and reduced their target price for the stock from $65.00 to $40.00 in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $59.00.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.